These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 23455927

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
    Padayatti PS, Helfand MS, Totir MA, Carey MP, Carey PR, Bonomo RA, van den Akker F.
    J Biol Chem; 2005 Oct 14; 280(41):34900-7. PubMed ID: 16055923
    [Abstract] [Full Text] [Related]

  • 6. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
    Helfand MS, Taracila MA, Totir MA, Bonomo RA, Buynak JD, van den Akker F, Carey PR.
    Biochemistry; 2007 Jul 24; 46(29):8689-99. PubMed ID: 17595114
    [Abstract] [Full Text] [Related]

  • 7. Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
    Totir MA, Helfand MS, Carey MP, Sheri A, Buynak JD, Bonomo RA, Carey PR.
    Biochemistry; 2007 Aug 07; 46(31):8980-7. PubMed ID: 17630699
    [Abstract] [Full Text] [Related]

  • 8. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.
    Padayatti PS, Helfand MS, Totir MA, Carey MP, Hujer AM, Carey PR, Bonomo RA, van den Akker F.
    Biochemistry; 2004 Feb 03; 43(4):843-8. PubMed ID: 14744126
    [Abstract] [Full Text] [Related]

  • 9. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
    Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA.
    Antimicrob Agents Chemother; 2010 Feb 03; 54(2):890-7. PubMed ID: 20008772
    [Abstract] [Full Text] [Related]

  • 10. Penam sulfones and β-lactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition.
    Rodkey EA, Winkler ML, Bethel CR, Pagadala SR, Buynak JD, Bonomo RA, van den Akker F.
    PLoS One; 2014 Feb 03; 9(1):e85892. PubMed ID: 24454944
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
    Therrien C, Kotra LP, Sanschagrin F, Mobashery S, Levesque RC.
    FEBS Lett; 2000 Mar 31; 470(3):285-92. PubMed ID: 10745083
    [Abstract] [Full Text] [Related]

  • 12. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
    Helfand MS, Totir MA, Carey MP, Hujer AM, Bonomo RA, Carey PR.
    Biochemistry; 2003 Nov 25; 42(46):13386-92. PubMed ID: 14621983
    [Abstract] [Full Text] [Related]

  • 13. Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitors.
    Kalp M, Bethel CR, Bonomo RA, Carey PR.
    Biochemistry; 2009 Oct 20; 48(41):9912-20. PubMed ID: 19736945
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam.
    Kuzin AP, Nukaga M, Nukaga Y, Hujer A, Bonomo RA, Knox JR.
    Biochemistry; 2001 Feb 13; 40(6):1861-6. PubMed ID: 11327849
    [Abstract] [Full Text] [Related]

  • 15. Detecting a quasi-stable imine species on the reaction pathway of SHV-1 β-lactamase and 6β-(hydroxymethyl)penicillanic acid sulfone.
    Che T, Rodkey EA, Bethel CR, Shanmugam S, Ding Z, Pusztai-Carey M, Nottingham M, Chai W, Buynak JD, Bonomo RA, van den Akker F, Carey PR.
    Biochemistry; 2015 Jan 27; 54(3):734-43. PubMed ID: 25536850
    [Abstract] [Full Text] [Related]

  • 16. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
    Totir MA, Padayatti PS, Helfand MS, Carey MP, Bonomo RA, Carey PR, van den Akker F.
    Biochemistry; 2006 Oct 03; 45(39):11895-904. PubMed ID: 17002290
    [Abstract] [Full Text] [Related]

  • 17. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
    Bethel CR, Taracila M, Shyr T, Thomson JM, Distler AM, Hujer KM, Hujer AM, Endimiani A, Papp-Wallace K, Bonnet R, Bonomo RA.
    Antimicrob Agents Chemother; 2011 Jul 03; 55(7):3465-75. PubMed ID: 21555770
    [Abstract] [Full Text] [Related]

  • 18. Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.
    Padayatti PS, Sheri A, Totir MA, Helfand MS, Carey MP, Anderson VE, Carey PR, Bethel CR, Bonomo RA, Buynak JD, van den Akker F.
    J Am Chem Soc; 2006 Oct 11; 128(40):13235-42. PubMed ID: 17017804
    [Abstract] [Full Text] [Related]

  • 19. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
    Payne DJ, Cramp R, Winstanley DJ, Knowles DJ.
    Antimicrob Agents Chemother; 1994 Apr 11; 38(4):767-72. PubMed ID: 8031044
    [Abstract] [Full Text] [Related]

  • 20. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
    Totir MA, Cha J, Ishiwata A, Wang B, Sheri A, Anderson VE, Buynak J, Mobashery S, Carey PR.
    Biochemistry; 2008 Apr 01; 47(13):4094-101. PubMed ID: 18324783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.